Is A Beat In The Cards For Humana's (HUM) Earnings In Q4?

Published 02/02/2020, 09:44 PM
Updated 07/09/2023, 06:31 AM
HUM
-
CLVSQ
-
TNDM
-
CHNG
-

Humana Inc.’s (NYSE:HUM) fourth-quarter 2019 results are scheduled to be reported on Feb 5, 2019.

The Zacks Consensus Estimate for earnings is pegged at $2.20, indicating a decline of 17% from the year-ago reported figure.

The consensus mark for revenues of $16.1 billion suggests an uptick of 14% from the prior-year reported number.

Factors to Impact Q4 Results

The company’s top line is likely to have witnessed an upside during the fourth quarter on the back of growth in premiums, and its strong Medicaid and Medicare lines of businesses.

However, the overall earnings might have been affected by lower number of members due to consequent decline in Prescription Drug Plan (PDP) enrolment. The consensus mark for Speciality membership hints at a fall of 26.8% from the year-ago reported figure.

Humana’s fourth-quarter earnings performance might also reflect escalating growth-related investments.

The company is expected to have enjoyed healthy operating cash flow in the quarter to be reported on the back of excellent operating efficiency and solid working capital.

Additionally, total investment income for the to-be-reported quarter might have noticed an uptrend. The consensus estimate for the same implies a 28.6% rise from the year-ago reported figure.

Per its last earnings call, management had supposedly made certain incremental investments in the fourth quarter, which include higher Medicare annual election period marketing spend plus increased sales and service costs related to the PDP plan changes, etc. An elevation in such expenditures might weigh down the company’s margins.

What the Quantitative Model States

Our proven model predicts an earnings beat for Humana this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of beating estimates, which you can see below. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Earnings ESP: Humana has an Earnings ESP of +0.15%. You can see the complete list of today’s Zacks #1 Rank stocks here.

Humana Inc. Price and EPS Surprise

Humana Inc. Price and EPS Surprise

Humana Inc. price-eps-surprise | Humana Inc. Quote

Zacks Rank: Humana carries a Zacks Rank #3, which increases the predictive power of ESP. Plus, its positive ESP makes us hopeful of a positive surprise in the upcoming quarterly release.

Highlights of Q3 Earnings and Surprise History

Humana’s third-quarter 2019 operating earnings per share of $5.03 beat both the Zacks Consensus Estimate and the year-over-year figure by 9.8%. This positivity can primarily be attributed to Medicare Advantage membership growth and higher revenues.

The company boasts a stellar earnings record, having delivered a positive surprise in all the trailing four quarters, the average being 8.6%.

Other Stocks to Consider

Some other stocks worth considering from the medical sector with the perfect combination of elements to also surpass estimates in the next releases are as follows:

Change Healthcare Inc. (NASDAQ:CHNG) has an Earnings ESP of +1.83% and a Zacks Rank of 1. The company is set to report fourth-quarter earnings on Feb 12.

Clovis Oncology, Inc. (NASDAQ:CLVS) has an Earnings ESP of +3.56% and a Zacks Rank #2. The company is set to report fourth-quarter earnings performance on Feb 24.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is slated to release fourth-quarter financial figures on Feb 24. The stock has an Earnings ESP of +27.59% and is Zacks #1 Ranked.

Free: Zacks’ Single Best Stock Set to Double

Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

See 5 Stocks Set to Double>>



Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report

Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report

Humana Inc. (HUM): Free Stock Analysis Report

Change Healthcare Inc. (CHNG): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.